SHATTUCK LABS INC (STTK)
US82024L1035 - Common Stock
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the
– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients;...
STTK Stock Earnings: Shattuck Labs Beats EPS, Beats Revenue for Q1 2024
STTK stock results show that Shattuck Labs beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
STTK Stock Earnings: Shattuck Labs Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shattuck Labs (NASDAQ:STTK) just reported results for the first quarter of 2024...
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of...
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
– Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade (ICB) acquired resistance; inhibition of TRIM7 with small molecule...
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
AUSTIN, TX & DURHAM, NC, April 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company...
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
- Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline Higher-Risk...
Shattuck Labs Announces Participation in Upcoming March Conferences
Shattuck Labs Announces Participation in Upcoming March Conferences
AUSTIN, TX and DURHAM, NC, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in multiple investor conferences in March 2024.
Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins
/PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a drug discovery...
Two Biotech/pharma stocks to watch - STTK, KALV
Despite positive tidings, shares of Shattuck Labs (STTK) and KalVista Pharmaceuticals (KALV) closed lower Tuesday. Is this a buy-the-dip opportunity?
Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases
AUSTIN, TX and DURHAM, NC, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company...
Shattuck Labs files to sell 3.1M shares for its holders (NASDAQ:STTK)
Shattuck Labs files prospectus for proposed resale of 3.1 million common shares by selling stockholders.
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024
Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
AUSTIN, TX and DURHAM, NC, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company...
Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
AUSTIN, TX and DURHAM, NC, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “company”) (NASDAQ: STTK), a clinical-stage...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day off right with a look at the biggest pre-market stock movers to watch for Thursday morning!
Shattuck Labs stock rallies 90% on Phase 1 data for blood cancer drug (STTK)
Shattuck Labs (STTK) stock surged 90% in the wake of Phase 1 topline results for its drug candidate SL-172154 in the treatment of certain types of MDS and AML. Read more here.
Wednesday Sector Leaders: Biotechnology, Rental, Leasing, & Royalty Stocks
EY Layoffs 2023: What to Know About the Latest EY Job Cuts
EY layoffs have been announced and this has the accounting firm cutting 130 jobs to adjust for slowing demand after the pandemic.
Why Is Shattuck Labs (STTK) Stock Up 93% Today?
Shattuck Labs stock is rising on Wednesday after the company provided positive initial results from a Phase 1 clinical trial.